Amgen (NASDAQ:AMGN) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of human therapeutics through advances in recombinant DNA and cellular biology. The company focuses on discovering, developing and manufacturing biologic medicines that address serious illnesses in areas such as oncology, inflammation, bone health, cardiovascular disease and nephrology.
Amgen’s commercial portfolio includes several widely prescribed biologics. Neulasta (pegfilgrastim) helps reduce the incidence of infection in patients undergoing chemotherapy, while Enbrel (etanercept) treats autoimmune conditions such as rheumatoid arthritis and psoriasis. Prolia and Xgeva (both denosumab) are therapies for bone-related diseases, and Repatha (evolocumab) is used to manage high cholesterol in patients at risk of cardiovascular events. The company continues to advance its pipeline with novel candidates in oncology, hematology and rare diseases.
Serving patients in more than 100 countries, Amgen maintains research, development and manufacturing facilities in North America, Europe and the Asia-Pacific region. Key production sites include biologics manufacturing plants in Puerto Rico and Ireland, complemented by R&D centers in California and Cambridge, Massachusetts. Amgen combines internal innovation with strategic collaborations and partnerships to accelerate the translation of scientific discoveries into new therapies.
Leadership at Amgen is anchored by Robert A. Bradway, who serves as chairman and chief executive officer. Under his tenure, the company has emphasized precision medicine, operational excellence and sustainability initiatives designed to improve global access to biotherapeutics. Amgen continues to invest heavily in research and development to expand its portfolio and meet evolving patient needs worldwide.
